Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

Hypercholesterolemia is a major risk factor for atherosclerosis. It also is associated with platelet hyperactivity, which increases morbidity and mortality from cardiovascular disease. However, the mechanisms by which hypercholesterolemia produces a procoagulant state remain undefined. Atherosclerosis is associated with accumulation of oxidized lipoproteins within atherosclerotic lesions. Small quantities of oxidized lipoproteins are also present in the circulation of patients with coronary artery disease. We therefore hypothesized that hypercholesterolemia leads to elevated levels of oxidized LDL (oxLDL) in plasma and that this induces expression of the procoagulant protein tissue factor (TF) in monocytes. In support of this hypothesis, we report here that oxLDL induced TF expression in human monocytic cells and monocytes. In addition, patients with familial hypercholesterolemia had elevated levels of plasma microparticle (MP) TF activity. Furthermore, a high-fat diet induced a time-dependent increase in plasma MP TF activity and activation of coagulation in both LDL receptor-deficient mice and African green monkeys. Genetic deficiency of TF in bone marrow cells reduced coagulation in hypercholesterolemic mice, consistent with a major role for monocyte-derived TF in the activation of coagulation. Similarly, a deficiency of either TLR4 or TLR6 reduced levels of MP TF activity. Simvastatin treatment of hypercholesterolemic mice and monkeys reduced oxLDL, monocyte TF expression, MP TF activity, activation of coagulation, and inflammation, without affecting total cholesterol levels. Our results suggest that the prothrombotic state associated with hypercholesterolemia is caused by oxLDL-mediated induction of TF expression in monocytes via engagement of a TLR4/TLR6 complex.

[1]  Paul J. Harrison,et al.  Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[2]  A. Basten,et al.  Faculty Opinions recommendation of Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. , 2011 .

[3]  N. Mackman,et al.  Microparticles in Hemostasis and Thrombosis , 2011, Circulation research.

[4]  T. Luther,et al.  Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. , 2010, Blood.

[5]  J. Luyendyk,et al.  Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein e4. , 2010, The American journal of cardiology.

[6]  L. Bernier,et al.  A new method for measurement of total plasma PCSK9: clinical applications , 2010, Journal of Lipid Research.

[7]  K. Moore,et al.  CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer , 2009, Nature Immunology.

[8]  D. Kirchhofer,et al.  Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice , 2009, Journal of thrombosis and haemostasis : JTH.

[9]  Andrew C. Li,et al.  Lipoprotein Accumulation in Macrophages via Toll-Like Receptor-4-Dependent Fluid Phase Uptake , 2009, Circulation research.

[10]  J. Freyssinet,et al.  Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. , 2009, Atherosclerosis.

[11]  P. Libby,et al.  A randomized trial of rosuvastatin in the prevention of venous thromboembolism. , 2009, The New England journal of medicine.

[12]  E. Horváth-Puhó,et al.  Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study , 2009, Journal of thrombosis and haemostasis : JTH.

[13]  F. Rosendaal,et al.  HMG‐CoA reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.

[14]  A. Khorana,et al.  Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer , 2008, Journal of thrombosis and haemostasis : JTH.

[15]  K. McCrae,et al.  Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. , 2008, The Journal of clinical investigation.

[16]  Seppo Ylä-Herttuala,et al.  Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. , 2008, Cardiovascular research.

[17]  P. Thampi,et al.  Dietary homocysteine promotes atherosclerosis in apoE-deficient mice by inducing scavenger receptors expression. , 2008, Atherosclerosis.

[18]  S. Hazen,et al.  Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype , 2007, Nature Medicine.

[19]  F. Kronenberg,et al.  Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[20]  K. Stokes,et al.  Tissue factor: a mediator of inflammatory cell recruitment, tissue injury, and thrombus formation in experimental colitis , 2007, The Journal of experimental medicine.

[21]  E. Tremoli,et al.  Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. , 2007, Pharmacological research.

[22]  Y. Castier,et al.  Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. , 2007, Journal of the American College of Cardiology.

[23]  P. Libby,et al.  Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering: A Potential Biomarker of Early Atherosclerosis Regression , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[24]  K. Williams,et al.  Cholesterol Enrichment of Human Monocyte/Macrophages Induces Surface Exposure of Phosphatidylserine and the Release of Biologically-Active Tissue Factor–Positive Microvesicles , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[26]  C. Esmon The interactions between inflammation and coagulation , 2005, British journal of haematology.

[27]  G. Vilahur,et al.  Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering , 2005, Thrombosis and Haemostasis.

[28]  H. Methe,et al.  Statins Decrease Toll-Like Receptor 4 Expression and Downstream Signaling in Human CD14+ Monocytes , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[29]  H. Methe,et al.  Expansion of Circulating Toll-Like Receptor 4–Positive Monocytes in Patients With Acute Coronary Syndrome , 2005, Circulation.

[30]  F. Peale,et al.  A monoclonal antibody that inhibits mouse tissue factor function , 2005, Journal of thrombosis and haemostasis : JTH.

[31]  M. Wolzt,et al.  Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo , 2005, Circulation.

[32]  Nigel Mackman,et al.  Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. , 2004, Blood.

[33]  W. Sasiela,et al.  High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial , 2004, Circulation.

[34]  E. Oger,et al.  Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case–control study , 2004, Fundamental & clinical pharmacology.

[35]  R. Rosenson Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. , 2004, Atherosclerosis.

[36]  N. Mackman,et al.  Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. , 2004, Blood.

[37]  T. Iwasaka,et al.  Increased level of oxidized LDL-dependent monocytederived microparticles in acute coronary syndrome , 2003, Thrombosis and Haemostasis.

[38]  M. Rosenfeld,et al.  Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. , 2003, Atherosclerosis.

[39]  K. Moore,et al.  Scavenger Receptors Class A-I/II and CD36 Are the Principal Receptors Responsible for the Uptake of Modified Low Density Lipoprotein Leading to Lipid Loading in Macrophages* , 2002, The Journal of Biological Chemistry.

[40]  B. Furie,et al.  Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse , 2002, Nature Medicine.

[41]  P. Libby,et al.  Statins Reduce Inflammation in Atheroma of Nonhuman Primates Independent of Effects on Serum Cholesterol , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[42]  E. Tremoli,et al.  Fluvastatin Reduces Tissue Factor Expression and Macrophage Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits in the Absence of Lipid Lowering , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[43]  F. Gruber,et al.  Analysis of inflammatory gene induction by oxidized phospholipids in vivo by quantitative real-time RT-PCR in comparison with effects of LPS. , 2002, Vascular pharmacology.

[44]  R. Westrick,et al.  Deficiency of Tissue Factor Pathway Inhibitor Promotes Atherosclerosis and Thrombosis in Mice , 2001, Circulation.

[45]  J. Witztum,et al.  Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. , 2001, Circulation.

[46]  P. Libby,et al.  An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.

[47]  J. Witztum,et al.  Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptor–Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[48]  R. Westrick,et al.  Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[49]  S. Basili,et al.  Inhibition of tissue-factor-mediated thrombin generation by simvastatin. , 2000, Atherosclerosis.

[50]  M. Penn,et al.  Native and Oxidized Low Density Lipoprotein Induction of Tissue Factor Gene Expression in Smooth Muscle Cells Is Mediated by Both Egr-1 and Sp1* , 1999, The Journal of Biological Chemistry.

[51]  R. Ross Atherosclerosis is an inflammatory disease , 1999 .

[52]  D. Rader,et al.  Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. , 1999, The Journal of clinical investigation.

[53]  F. Werf,et al.  Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. , 1998, Circulation.

[54]  P. Carmeliet,et al.  Low levels of tissue factor are compatible with development and hemostasis in mice. , 1998, The Journal of clinical investigation.

[55]  S. Basili,et al.  Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia , 1997, The Lancet.

[56]  E. Tremoli,et al.  Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[57]  J. Fallon,et al.  In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[58]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[59]  S. Young,et al.  Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[60]  K. Williams,et al.  The response-to-retention hypothesis of early atherogenesis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[61]  S. Kaul,et al.  Altered vascular responses to platelets from hypercholesterolemic humans. , 1993, Circulation research.

[62]  T. Bocan,et al.  Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography. , 1991, Journal of lipid research.

[63]  Haihua,et al.  Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. , 1991, The American journal of pathology.

[64]  V. Armstrong,et al.  Enhanced procoagulatory activity (PCA) of human monocytes/macrophages after in vitro stimulation with chemically modified LDL. , 1989, Atherosclerosis.

[65]  Kathleen M. Smith,et al.  Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[66]  J. Neaton,et al.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.

[67]  E. Haber,et al.  Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. , 1983, Science.

[68]  S. Kaul,et al.  Dose-dependent modulation of tissue factor protein and procoagulant activity in human monocyte-derived macrophages by oxidized low density lipoprotein. , 2011, Journal of atherosclerosis and thrombosis.

[69]  Li Zhou,et al.  Increased expression of Toll like receptor 4 on peripheral‐blood mononuclear cells in patients with coronary arteriosclerosis disease , 2006, Clinical and experimental immunology.

[70]  T. Wakefield,et al.  Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. , 2005, Blood.

[71]  Bernd R Binder,et al.  Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. , 2002, Blood.

[72]  F. Bruni,et al.  Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin , 2000, International journal of clinical & laboratory research.

[73]  A. Chang,et al.  Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. , 1998, Blood.

[74]  D. Steinberg,et al.  Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.